Active drug metabolites in drug development

Current Opinion in Pharmacology

Volumn 3, Issue 1, 2003, Pages 98-100

  Gad, Shayne C ^a  

^a Gad Consulting Services   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ANTIMALARIAL AGENT; ANTIRHEUMATIC AGENT; DIHYDROCODEINE; DRUG METABOLITE; ERDOSTEINE; ESCITALOPRAM; ESONARIMOD; FLUOXETINE; FLUTAMIDE; HALOFANTRINE; HALOPERIDOL; LOSARTAN; MOLSIDOMINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUROLEPTIC AGENT; PENCLOMEDINE; PRULIFLOXACIN; RAMOSETRON; REMACEMIDE; ROXIFIBAN; SIBUTRAMINE; SILDENAFIL; TAMOXIFEN; TAZAROTENE; TERFENADINE; UNINDEXED DRUG;

ACNE; ANGINA PECTORIS; AREA UNDER THE CURVE; BACTERIAL INFECTION; CELL PROTECTION; CONVULSION; DEPRESSION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MARKETING; DRUG METABOLISM; DRUG SAFETY; DRUG SCREENING; HEALTH CARE ORGANIZATION; HUMAN; HYPERTENSION; IMPOTENCE; MALARIA; OBESITY; POSTOPERATIVE PAIN; PRIORITY JOURNAL; PROSTATE CANCER; PSYCHOSIS; QUANTITATIVE ASSAY; REVIEW; RHEUMATIC DISEASE;

ANIMALS; HUMANS; PHARMACEUTICAL PREPARATIONS; TECHNOLOGY, PHARMACEUTICAL;

EID: 0037302084     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4892(02)00003-6     Document Type: Review

References (34)

1. Kristal BS, Vineau-Callahan K, Matson WR: Simultaneous analysis of multiple redox-active metabolites from biological matrices. Methods Mol Biol 2002, 186:185-194.
2. Maul C, Sattler I, Zerlin M, Hinze C, Koch C, Maier A, Grabley S, Thiercke R: Biomolecular-chemical screening: a novel screening approach for the discovery of biologically active secondary metabolites. III. New DNA-binding metabolites. J Antibiot (Tokyo) 1999, 52:1124-1134.
3. Sadzuka Y: Effective prodrug liposome and conversion to active metabolite. Curr Drug Metab 2000, 1:31-48.
4. Pirmohamed M, Kitteringham N, Park, B: The role of active metabolites in drug toxicity. Drug Saf 1994, 11:114-144.
5. Cambell D: The use of toxicokinetics for the safety assessment of drugs acting in the brain. Mol Neurobiol 1995, 11:193-216.
6. ICH: Toxicokenetics: the assessement of systemic exposure in toxicity studies. ICH S34 1995. URL: http://pharmacos.eudra.org/ F2/eudaralex/vol-3/pdfs-en/3bs10ae.pdf
7. CDER: Immediate release solid oral dosage forms CMC5. 1995. URL. http://www.fda.gov/cder/guidance/cmcf.pdf
8. CDER: Guidance for industry: drug metabolism/drug interaction studies in the drug development process: studies in vitro. USFDA 1997. URL: http://www.fda.gov/cder/guidance/clin3.pdf
9. Drauyer D: Pharmacologically active drug metabolites: therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure. Clin Pharmacokinet 1976, 1: 426-443.
10. Daratlini S: Active drug metabolites. Clin Pharmacokinet 1985, 10:216-227.
11. Pang K: A review of metabolite kinetics. J Pharmocokin Biopharm 1985; 13: 633-662.
12. Shuh R: Clinical pharmacokinetics: current requirements and future perspectives from a regulartory point of view. Xenobiotica 1993; 23: 1159-1193.
13. Bohme E: Pharmakologie von Molsidomin und seimen aktiven Metabolitem. Med Klin 1990, 85(Suppl 1):7-10. [Title translation: Pharmacology of molsidomine and its active metabolite.].
14. Levy R, Thummel K, Trager W, Hansten P, Eichelbaum M: Metabolic Drug Interactons. Philadelphia: Lippincott Williams and Wilkins; 2000.
15. Marks R: Pharmacokinetics and safey review of tazarotene. J Am Acad Dermatol 1998, 39:134-138.
16. Wesche D, Schuster B, Wang W, Woosley R: Mechanism of cardiotoxicity of halofantrine. Clin Pharmacol Ther 2001, 67:521-529.
17. Squires K: An introduction to nucleosides and nucleoside analogues. Antivir Ther 2001, 6(Suppl 3):1-14.
18. Collins J: Phase 1 clinical studies. In Principles of Clinical Pharmacology. Edited by Atkinson A, Daniels C, Dedrick R, Graudzinskas C, Markey S. San Diego, CA: Academic Press; 2001:395-400.
19. DeVane C: Translational pharmacokinetics: current issues with newer anti-derpressants. Depress Anxiety 1998, 8(Suppl 1):64-70.
20. Lacassie E, Gaulier JM, Marquet P, Rabatel JF, Lachatre G: Methods for the determination of seven selective serotonin reuptake inhibitors and three active metabolites in human serum using high-performance liquid chromatography and gas chromatography. J Chromatogr B Biomed Sci Appl 2000, 742:229-238.
21. Baillie T, Cayen M, Fouda H, Gerson R, Green J, Grossman L, Klunk L, LeBlanc B, Perkins D, Shipley L: Drug metabolites in safety testing. Tox Appl Pharmacol 2002, 182:188-196.
22. Cayen M: Metablite measurement - when is it important; what should be the criteria. AAPS Workshop on Biopharmaceutics in the New Millenium: Regulatory Approaches to Bioavailability and Bioequivalence. Washington, DC: APS; 2000.
23. Atkinson AJ, Strong J: Effect of active drug metabolites on plasma level response correlations. J Pharmacokinet Biopharm 1977, 5:95-109.
24. Atkinson A, Stec G, Lertora J, Ruo T, Thermat J: Impact of active metabolite on monitoring plasma concentrations of therapeutic drugs. Ther Drug Monit 1980, 2:19-27.
25. Bonner HS, Shaw LM: New dosing regimens for amifostine: a pilot study to compare the relative bioavailability of oral and subcutaneous administration with intravenous infusion. J Clin Pharmacol 2002, 42:166-174.
26. Ammon S. Hofmann U, Gugeler N, Mikus G: Pharmacokinetics of dihydrocodeine and its active metabolite after single and multiple oral dosing. Br J Clin Pharmacol 1999, 48:317-322.
27. Green R, Houghton R, Scarth J, Gregory C: Determination of fluoxetine and its major active metabolite norfluoxetine in huma plasma by liquid chromatography-tandem mass spectrometry. Chromatographia 2002, 55:S133-S136.
28. Igarashi K: The possible role of an active metabolite derived from the neuroleoptic agent haloperidol in drug-induced parkinsonism. J Toxicol Toxin Rev 1998, 17:27-38.
29. Sugimoto M, Inoue T, Takeshita K, Nakamura H, Yodoi J: Effects of a new anti-rheumatic drug KE-298 and its active metabolite: KE-758 on secretion of thiotedoxin and on the level of intracellular glutathione in human monocytes and T cells. Mol Immunol 2002, 38:793-799.
30. Suzuki J, Ohta H, Hanada K, Kawai N, Ikeda T, Nakao M, Ikemoto F, Nishikibe M: Acute effects of E-3174, a human active metabolite of losartan, on the cardiovascular system in tachycardia-induced canine heart failure. Hypertens Res 2001, 24:65-74.
31. Prats G, Roig C. Miro E, Navarro F, Mirelis B: In vitro activity of the active metabolite of prulifloxacin (AF 3013) compared with six other flouroquinolones. Eur J Clin Microbiol Infect Dis 2002, 21:328-334.
32. Ogata A, Yamaha Y, Sugiura M, Takayanagi R, Sawada Y, Iga T: Analysis of 5-HT3 receptor antagonist, ramosetron hydrochloride, based on recptor occupancy considering its active metabolite. Yakugaku Zasshi 2001, 121:793-798.
33. Pieniasek HJ Jr, Sy SKB, Ebling W, Fossler MJ, Cin VA, Mondick JT, Ma S, Kornhauser DM: Safety, tolerability, pharmacokinetics, and time course of pharmacologic response of the active metabolite of roxifian, XV459, a glycoprotein IIb/IIIa antagonist, following oral administration in healthy volunteers. J Clin Pharmacol 2002, 42:738-753.
34. Rodriguez OJF, Santana J, Febo I, Diaz C, Rodriguez JL, Garcia R, Font E, Rosario O: Intacellular studies of the necleoside reverse transcriptase inhibitor active metabolite: a review. PR Health Sci J 2001, 19:19-27.